{"id":"sal-0951","safety":{"commonSideEffects":[]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Without publicly available detailed mechanism information, SAL-0951's exact molecular target and pathway remain unclear. As a Phase 3 asset from Shenzhen Salubris Pharmaceuticals, it is undergoing late-stage clinical development, but comprehensive mechanistic data has not been widely disclosed in accessible literature.","oneSentence":"SAL-0951 is a small molecule inhibitor targeting a specific molecular pathway involved in disease pathogenesis.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:33:12.213Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[]},"trialDetails":[{"nctId":"NCT06737081","phase":"PHASE2","title":"SAL-0951 in the Treatment of Chemotherapy-induced Anemia in Patients With Non-myeloid Malignancies","status":"RECRUITING","sponsor":"Shenzhen Salubris Pharmaceuticals Co., Ltd.","startDate":"2024-09-14","conditions":"Anemia","enrollment":60},{"nctId":"NCT06720025","phase":"PHASE3","title":"Study of SAL-0951 Compared to Recombinant Human Erythropoietin in Anemic Patients Receiving Maintenance Hemodialysis","status":"COMPLETED","sponsor":"Shenzhen Salubris Pharmaceuticals Co., Ltd.","startDate":"2023-09-19","conditions":"Anemia","enrollment":100},{"nctId":"NCT06720233","phase":"PHASE3","title":"Efficacy and Safety Study of SAL-0951 in the Treatment of Renal Anemia in Patients Receiving Peritoneal Dialysis","status":"COMPLETED","sponsor":"Shenzhen Salubris Pharmaceuticals Co., Ltd.","startDate":"2002-02-22","conditions":"Anemia","enrollment":37},{"nctId":"NCT06016036","phase":"PHASE3","title":"SAL-0951 Tablets in the Treatment of Renal Anemia in Non-dialysis Chronic Kidney Disease","status":"COMPLETED","sponsor":"Shenzhen Salubris Pharmaceuticals Co., Ltd.","startDate":"2020-12-08","conditions":"Renal Anemia in Non-dialysis Chronic Kidney Disease","enrollment":156}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["SAL-0951 group"],"phase":"phase_3","status":"active","brandName":"SAL-0951","genericName":"SAL-0951","companyName":"Shenzhen Salubris Pharmaceuticals Co., Ltd.","companyId":"shenzhen-salubris-pharmaceuticals-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}